A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01416259
Recruitment Status : Completed
First Posted : August 15, 2011
Last Update Posted : August 4, 2015
Information provided by (Responsible Party):
Heron Therapeutics

August 10, 2011
August 15, 2011
August 4, 2015
July 2011
October 2011   (Final data collection date for primary outcome measure)
QTc Prolongation [ Time Frame: From baseline over 48 hours. ]
To evaluate the effect of APF530 given subcutaneously, in normal volunteers, on placebo subtracted change of QTcF
Same as current
Complete list of historical versions of study NCT01416259 on Archive Site
Plasma concentrations of granisetron [ Time Frame: From baseline over 48 hours ]
To achieve a mean Cmax of granisetron and AUC exposure in normal volunteers equivalent to that achieved by APF530 given subcutaneously, in patients.
Same as current
Not Provided
Not Provided
A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
A Randomized, Placebo-Controlled, Four-Period Crossover Definitive QT Study Of The Effects of APF530 Exposure, High-Dose IV Granisetron and Moxifloxacin on QTc Prolongation

This Phase I study will be performed in a double-blind, randomized, crossover design in healthy male and female subjects. The central ECG laboratory will be blinded to treatment. Every effort will be made to enroll equal numbers of males and females into the study.

Eligible subjects will participate in a screening phase (within 28 days of the dosing day), a treatment phase and a final visit, which will be conducted on discharge from the study. Study duration will be 32 days with a total of approximately 12 days of confinement. During the resting ECG periods, 12-lead digital ECGs will be extracted from continuous telemetry at selected time points to assess potential ECG effects. Blood samples for PK evaluation will be collected in conjunction with the ECG time points.

Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Healthy Male and Female Subjects
Drug: Withdraw treatment
APF530 Exposure, Granisetron and Moxifloxacin, Placebo
Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo
Intervention: Drug: Withdraw treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects in good health
  • aged between 18-50 years
  • weigh at least 50 kg (110 pounds)
  • have a body mass index of 18-32 kg/m2 inclusive
  • capable of understanding and complying with the protocol
  • have signed the informed consent

Exclusion Criteria:

  • have a history of drug abuse or are current smokers
  • have a known hypersensitivity to Moxifloxacin or granisetron
  • a history or presence of clinically significant abnormal 12-lead ECG or an ECG with QTc by Bazett's correction of > 450 ms in men, > 470 ms in women on the screening ECG
  • PR > 240 ms, QRS > 110 ms or a history of prolongation of QT interval
  • a family history of Long QT Syndrome or cardiac disease
  • may not have used any medications or consumed any foods contraindicated in the protocol
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
APPA C2011-01
Not Provided
Not Provided
Heron Therapeutics
Heron Therapeutics
Not Provided
Principal Investigator: Albert Dietz, MD, PhD Spaulding Clinical Research LLC
Heron Therapeutics
August 2015